Linical Co., Ltd. (2183.T)
JPY 290.0
(-0.68%)
JPY 290.0
(-0.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.7 Billion JPY | -6.88% |
| 2022 | 2.9 Billion JPY | 15.02% |
| 2021 | 2.52 Billion JPY | 9.14% |
| 2020 | 2.31 Billion JPY | -8.36% |
| 2019 | 2.52 Billion JPY | -2.88% |
| 2018 | 2.6 Billion JPY | 54.17% |
| 2017 | 1.68 Billion JPY | 9.57% |
| 2016 | 1.53 Billion JPY | 6.77% |
| 2015 | 1.44 Billion JPY | 58.17% |
| 2014 | 911.44 Million JPY | 27.57% |
| 2013 | 714.46 Million JPY | 9.8% |
| 2012 | 650.68 Million JPY | 4.06% |
| 2011 | 625.27 Million JPY | -7.12% |
| 2010 | 673.19 Million JPY | 14.91% |
| 2009 | 585.82 Million JPY | 2.06% |
| 2008 | 573.98 Million JPY | 117.75% |
| 2007 | 263.59 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 789 Million JPY | 24.88% |
| 2023 Q1 | 835.33 Million JPY | 27.4% |
| 2023 Q3 | 678.36 Million JPY | -6.83% |
| 2023 FY | 2.7 Billion JPY | -6.88% |
| 2023 Q4 | 631.82 Million JPY | -6.86% |
| 2023 Q2 | 728.06 Million JPY | -12.84% |
| 2022 FY | 2.9 Billion JPY | 15.02% |
| 2022 Q4 | 655.69 Million JPY | -16.18% |
| 2022 Q3 | 782.29 Million JPY | 10.16% |
| 2022 Q2 | 710.14 Million JPY | -6.18% |
| 2022 Q1 | 756.9 Million JPY | 10.72% |
| 2021 Q1 | 566.84 Million JPY | 4.65% |
| 2021 Q2 | 602.2 Million JPY | 6.24% |
| 2021 Q3 | 673.02 Million JPY | 11.76% |
| 2021 Q4 | 683.59 Million JPY | 1.57% |
| 2021 FY | 2.52 Billion JPY | 9.14% |
| 2020 Q2 | 552.1 Million JPY | -11.43% |
| 2020 Q3 | 597.02 Million JPY | 8.14% |
| 2020 FY | 2.31 Billion JPY | -8.36% |
| 2020 Q4 | 541.65 Million JPY | -9.27% |
| 2020 Q1 | 623.38 Million JPY | -3.05% |
| 2019 Q2 | 651.72 Million JPY | 6.42% |
| 2019 Q1 | 612.39 Million JPY | 3.21% |
| 2019 Q3 | 618.2 Million JPY | -5.14% |
| 2019 Q4 | 643 Million JPY | 4.01% |
| 2019 FY | 2.52 Billion JPY | -2.88% |
| 2018 FY | 2.6 Billion JPY | 54.17% |
| 2018 Q4 | 593.32 Million JPY | -2.87% |
| 2018 Q3 | 610.86 Million JPY | -2.57% |
| 2018 Q2 | 626.99 Million JPY | -18.47% |
| 2018 Q1 | 769.03 Million JPY | 81.62% |
| 2017 Q4 | 423.43 Million JPY | 2.53% |
| 2017 FY | 1.68 Billion JPY | 9.57% |
| 2017 Q2 | 411.67 Million JPY | -6.13% |
| 2017 Q3 | 412.97 Million JPY | 0.31% |
| 2017 Q1 | 438.54 Million JPY | 11.02% |
| 2016 FY | 1.53 Billion JPY | 6.77% |
| 2016 Q3 | 395.01 Million JPY | 8.01% |
| 2016 Q2 | 365.73 Million JPY | -4.65% |
| 2016 Q4 | 394.99 Million JPY | -0.0% |
| 2016 Q1 | 383.56 Million JPY | -3.2% |
| 2015 FY | 1.44 Billion JPY | 58.17% |
| 2015 Q4 | 396.25 Million JPY | 4.66% |
| 2015 Q3 | 378.6 Million JPY | 16.95% |
| 2015 Q2 | 323.74 Million JPY | -5.62% |
| 2015 Q1 | 343.03 Million JPY | 9.21% |
| 2014 FY | 911.44 Million JPY | 27.57% |
| 2014 Q4 | 314.11 Million JPY | 56.74% |
| 2014 Q3 | 200.4 Million JPY | 9.8% |
| 2014 Q2 | 182.5 Million JPY | -14.89% |
| 2014 Q1 | 214.42 Million JPY | 20.53% |
| 2013 Q1 | 182.2 Million JPY | -2.6% |
| 2013 FY | 714.46 Million JPY | 9.8% |
| 2013 Q3 | 181.3 Million JPY | 4.76% |
| 2013 Q4 | 177.9 Million JPY | -1.88% |
| 2013 Q2 | 173.06 Million JPY | -5.02% |
| 2012 Q3 | 163.79 Million JPY | 9.41% |
| 2012 Q1 | 150.11 Million JPY | -1.28% |
| 2012 Q2 | 149.71 Million JPY | -0.26% |
| 2012 Q4 | 187.05 Million JPY | 14.2% |
| 2012 FY | 650.68 Million JPY | 4.06% |
| 2011 FY | 625.27 Million JPY | -7.12% |
| 2011 Q1 | 163.39 Million JPY | -7.42% |
| 2011 Q2 | 144.88 Million JPY | -11.33% |
| 2011 Q3 | 164.94 Million JPY | 13.84% |
| 2011 Q4 | 152.05 Million JPY | -7.81% |
| 2010 FY | 673.19 Million JPY | 14.91% |
| 2010 Q2 | 161.02 Million JPY | 2.2% |
| 2010 Q1 | 157.55 Million JPY | 8.85% |
| 2010 Q3 | 178.13 Million JPY | 10.62% |
| 2010 Q4 | 176.48 Million JPY | -0.92% |
| 2009 Q1 | 132.65 Million JPY | -9.77% |
| 2009 FY | 585.82 Million JPY | 2.06% |
| 2009 Q4 | 144.74 Million JPY | -12.62% |
| 2009 Q3 | 165.65 Million JPY | 16.02% |
| 2009 Q2 | 142.78 Million JPY | 7.64% |
| 2008 Q4 | 147.01 Million JPY | -8.8% |
| 2008 Q2 | 144.69 Million JPY | 0.0% |
| 2008 FY | 573.98 Million JPY | 117.75% |
| 2008 Q3 | 161.2 Million JPY | 11.41% |
| 2007 FY | 263.59 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -110.607% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -368.988% |
| GNI Group Ltd. | 9.32 Billion JPY | 70.982% |
| Trans Genic Inc. | 2.15 Billion JPY | -25.25% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -81.415% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 11.914% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -45.677% |
| AnGes, Inc. | 8.9 Billion JPY | 69.612% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -186.846% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 85.903% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -555.026% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -177.35% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | -5.36% |
| CanBas Co., Ltd. | 278 Million JPY | -873.091% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -136.978% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -48.805% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -68.678% |
| Kidswell Bio Corporation | 2.37 Billion JPY | -13.948% |
| PeptiDream Inc. | 9.68 Billion JPY | 72.075% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -37.978% |
| Ribomic Inc. | 1.1 Billion JPY | -144.661% |
| SanBio Company Limited | 4.53 Billion JPY | 40.401% |
| Healios K.K. | 3.48 Billion JPY | 22.421% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -134.269% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -102.717% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -92.751% |
| StemRIM | 2.07 Billion JPY | -30.308% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -37.774% |
| FunPep Company Limited | 313.82 Million JPY | -762.018% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -182.376% |
| Stella Pharma Corporation | 963.98 Million JPY | -180.626% |
| TMS Co., Ltd. | 943.25 Million JPY | -186.794% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -148.194% |
| Cuorips Inc. | 598.11 Million JPY | -352.284% |
| K Pharma,Inc. | 543.94 Million JPY | -397.331% |
| Takara Bio Inc. | 23.9 Billion JPY | 88.684% |
| ReproCELL Incorporated | 1.51 Billion JPY | -78.677% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -128.481% |
| StemCell Institute Inc. | 1.16 Billion JPY | -132.78% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -77.707% |
| CellSeed Inc. | 804.93 Million JPY | -236.078% |